NeuroPhage extends Series B to $21.4M

March 8, 2012

CAMBRIDGE, March 1, 2012 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a privately held biotechnology company focused on a novel approach for disaggregating misfolded proteins for the treatment and prevention of neurodegenerative diseases, announced today that it has secured $9.0 million in Series B-1. Dr. Michael Grundman, an Alzheimer’s disease clinical expert, President and CEO of the consulting firm Global R& D Partners, LLC, has joined the NeuroPhage team  to lead the clinical development of NPT002. The round was completed by existing investors, including Merieux Développement, Shire, and private investors.  The Series B-1 financing brings the total amount of equity capital raised by NeuroPhage since its inception in 2006 to $28.6 million.  The terms of the financing were not disclosed. 

Dr. Richard Fisher, NeuroPhage’s CSO said: “The continued support of all of our investors enables us to fully exploit our recent breakthrough around the mechanism of action of NPT002.”

About NeuroPhage

NeuroPhage is a biotechnology company focusing on a unique approach for treating diseases involving protein aggregation. NeuroPhage was founded in 2007 by a Cambridge-based team along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.